RxDoctor Payments Data

Scott Jones, MD

Cardiovascular Disease · Indianapolis, INNPI 1346290897

Payments from drug & device makers

$1,022in general payments, 2019–2025

Across 54 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$203
  • Amgen$200
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$176
  • Novartis$106
  • Boehringer Ingelheim$69
  • Boston Scientific$65
  • plus $203 from 11 others

What the payments were for

  • Food & beverage$1,022100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,022 in reported general payments places this provider in the 30th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$123,243
Medicare patients
834
Services billed
1,823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban412$516,409
EntrestoSacubitril/Valsartan51$71,356
JardianceEmpagliflozin75$64,445
Repatha SureclickEvolocumab64$61,048
XareltoRivaroxaban45$58,535
Praluent PenAlirocumab21$22,509
Repatha SyringeEvolocumab12$6,964
Ranolazine ErRanolazine48$6,904
Metoprolol Succinate505$5,408
Torsemide139$2,790
Valsartan157$2,766
Atorvastatin Calcium305$2,700
Dabigatran EtexilateDabigatran Etexilate Mesylate15$2,353
Rosuvastatin Calcium249$2,082
ClopidogrelClopidogrel Bisulfate174$1,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$516,409412 claims
NovartisEntresto$106$71,35651 claims
Boehringer IngelheimJardiance$69$64,44575 claims
Johnson & JohnsonXarelto$27$58,53545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →